A recent New York Times article about the safety of Miralax and similar generic products used to treat children with constipation has struck an alarming chord with many parents.
Miralax and its generic equivalents are one of our first-line-of-defense tools for managing chronic, severe constipation. The ingredient called into question is polyethylene glycol 3350, or PEG 3350. There has been a tremendous amount of investigation into the safety of PEG 3350. In fact, it’s probably one of the most thoroughly studied molecules in our field. The available research provides a strong justification for PEG 3350 as a treatment for childhood constipation, considering both the safety and efficacy of this molecule relative to other medicines sometimes prescribed for severe constipation.